A detailed history of Vanguard Group Inc transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 598,694 shares of CYTH stock, worth $413,098. This represents 0.0% of its overall portfolio holdings.

Number of Shares
598,694
Previous 446,573 34.06%
Holding current value
$413,098
Previous $567,000 16.75%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.64 - $1.38 $97,357 - $209,926
152,121 Added 34.06%
598,694 $472,000
Q2 2024

Aug 13, 2024

BUY
$1.16 - $1.53 $57,901 - $76,369
49,915 Added 12.58%
446,573 $567,000
Q1 2024

May 10, 2024

BUY
$1.39 - $1.9 $57,594 - $78,726
41,435 Added 11.66%
396,658 $551,000
Q4 2023

Feb 14, 2024

BUY
$0.93 - $1.88 $68,072 - $137,608
73,196 Added 25.95%
355,223 $564,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $1.88 $27,279 - $40,702
21,650 Added 8.31%
282,027 $400,000
Q2 2023

Aug 14, 2023

BUY
$0.67 - $2.3 $4,351 - $14,938
6,495 Added 2.56%
260,377 $413,000
Q4 2022

Feb 10, 2023

BUY
$0.95 - $2.13 $111 - $249
117 Added 0.05%
253,882 $360,000
Q2 2022

Aug 12, 2022

SELL
$1.97 - $3.21 $2,561 - $4,173
-1,300 Reduced 0.51%
253,765 $500,000
Q1 2022

May 13, 2022

BUY
$2.62 - $4.51 $2,001 - $3,445
764 Added 0.3%
255,065 $808,000
Q4 2021

Feb 14, 2022

BUY
$3.47 - $7.34 $286,691 - $606,430
82,620 Added 48.12%
254,301 $948,000
Q3 2021

Nov 12, 2021

BUY
$6.21 - $10.04 $125,075 - $202,215
20,141 Added 13.29%
171,681 $1.16 Million
Q2 2021

Aug 13, 2021

BUY
$6.58 - $10.85 $997,133 - $1.64 Million
151,540 New
151,540 $1.55 Million

Others Institutions Holding CYTH

About Cyclo Therapeutics, Inc.


  • Ticker CYTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 8,439,440
  • Market Cap $5.82M
  • Description
  • Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...
More about CYTH
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.